Which pneumococcal vaccine should be used in adults?
American Pharmacists Association News, 05/15/2012
FDA approved pneumococcal 13–valent protein conjugate vaccine for use in adults older than 50 years.1 This was an accelerated approval based on immunogenicity data. The Advisory Committee on Immunization Practices (ACIP) has determined that insufficient evidence exists to determine the role of PCV13 in adults older than 50 years. For now, the recommendation to use the 23–valent pneumococcal polysaccharide vaccine remains in effect.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.